The report will be delivered in 2-3 business days.

Blood Cancer Drugs Global Market Report 2019

Starting Price : $ 4000.00 | Pages : 200 | Published : October 2019 | SKU CODE : 7215 | Format :


The blood cancer drugs market consists of sales of drugs to treat all types of blood cancers. The blood cancer drugs market excludes biologics and includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating leukemia, lymphoma, and myeloma. The blood cancer drugs include Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin) and others

The global blood cancer drugs market was valued at about $33 billion in 2018 and is expected to grow to $43.74 billion at a CAGR of 7.3% through 2022.

North America was the largest region in the blood cancer drugs market in 2018, followed by Europe. This region is expected to remain the largest during the next five years. The blood cancer drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

The blood cancer drugs market is being driven by the growing death incidences and increasing prevalence of blood cancer cases across the globe. Different types of blood cancers such as lymphoma, leukemia, myeloma and others have different risk factors where some can be controlled or prevented through drug therapies and others may lead to death. According to 2018 Bristol-Myers Squibb Company report, over 1.85 million new blood cancer cases are expected to be diagnosed across the globe in 2040, out of which 918,872 cases are from lymphoma, 656,345 from leukemia, and 275,047 cases myeloma. Furthermore the report estimated, in 2040, the approximate number of deaths worldwide due to blood cancer will be 1,100,000. In 2019, more than 387,000 people are living with leukemia in the United States and an estimated 68,000 deaths will result from blood cancer. According to national cancer institute, the estimated deaths due to blood cancer are expected to be around 22,840 in 2019. The increasing deaths and increasing incidence of blood cancer cases globally drives the blood cancer drug market.

Drug approval involves series of research stages and regulatory approvals that are often expensive. Drug approval process include about four phases of clinical trials and various stages of screening process with the regulatory body such as FDA. The costs of failed clinical trials is also high as clinical trial phases involves huge investments. According to Tufts Center for the Study of Drug Development, the cost of bringing a new drug from its conception to shelves is about $2.7 billion in 2017. This cost has increased more than 10 folds, with the cost of bringing a new drug to the market being $320 million in 1990s. Thus indicating that the high drug approval costs hinders the growth of the blood cancer drugs market.

Companies in the blood cancer drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels. This technology helps to analyze large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching blood cancer patients with the most relevant clinical trials, thus lowering clinical trial costs. Major blood cancer drug manufacturers such as Roche, Pfizer and Johnson and Johnson have already invested in AI technologies to reduce time taken and costs incurred for drug development. For instance, Johnson and Johnson entered into an agreement with BenevolentAI, a UK-based artificial intelligence company (start-up), to mine data for designing new blood cancer drugs.

The Food and Drug Administration (FDA) is a federal agency regulating the blood cancer drugs market. In June 2019, FDA declined to approve Daiichi Sankyo's leukemia drug for blood cancer treatment. Daiichi Sankyo, a global pharmaceutical company developing, importing and marketing pharmaceutical products received a rejection notice on its drug - quizartinib used for treating adults with a type of blood cancer. The rejection of drug was due to the negative impact caused after the intake which resulted in FDA's statement saying faulty application for blood cancer treatment in an internal review. To avoid the incidences caused by such medicines in treating medical conditions such as blood cancer, FDA has declined to the approval.

In 2019, Eli Lilly, a US-based Pharmaceutical company, acquired Loxo Oncology, a cancer-focused biotechnology company for $8 billion. This acquisition of Loxo Oncology provides Lilly with a promising pipeline of investigational medicines such as oral RET inhibitor, oral BTK inhibitor and others. The deal would enable Lilly to attain strong patent on Loxo's genetically based approach to treat cancer. Loxo Oncology, is a biopharmaceutical company, developing and selling medicines for patients with genetically defined cancers. The company focuses on building small molecule cancer drugs for genetically defined cancer patients. The company was founded in 2013 and is headquartered in Stamford, Connecticut, USA.

Major players in the market are Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly

    1. Executive Summary

    2. Blood Cancer Drugs Market Characteristics

    3. Blood Cancer Drugs Market Size And Growth

    3.1. Global Blood Cancer Drugs Historic Market, 2014 - 2018, $ Billion

    3.1.1. Drivers Of The Market

    3.1.2. Restraints On The Market

    3.2. Global Blood Cancer Drugs Forecast Market, 2018 - 2022F, 2025F, 2030F, $ Billion

    3.2.1. Drivers Of The Market

    3.2.2. Restraints On the Market

    4. Blood Cancer Drugs Market Segmentation

    4.1. Global Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    Leukemia

    Lymphoma

    Myeloma

    4.2. Global Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    Rituaxan/Mabthera (Rituximab)

    Gleevac/Glivec (Imatinib)

    Revlimid (Lenalidomide)

    Velcade (Bortezomib)

    Tasigna (Nilotinib)

    Pomalyst (Pomalidomide)

    Vidaza (Azacitidine)

    Kyprolis (Carfilzomib)

    Adcetris (Brentuximab Vedotin)

    Others

    5. Blood Cancer Drugs Market Regional And Country Analysis

    5.1. Global Blood Cancer Drugs Market, Split By Region, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    5.2. Global Blood Cancer Drugs Market, Split By Country, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    6. Asia-Pacific Blood Cancer Drugs Market  

    6.1. Asia-Pacific Blood Cancer Drugs Market Overview  

    6.2. Asia-Pacific Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    6.3. Asia-Pacific Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    7. China Blood Cancer Drugs Market  

    7.1. China Blood Cancer Drugs Market Overview  

    7.2. China Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F,$ Billion

    7.3. China Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F,$ Billion

    8. India Blood Cancer Drugs Market  

    8.1. India Blood Cancer Drugs Market Overview  

    8.2. India Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    8.3. India Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    9. Japan Blood Cancer Drugs Market  

    9.1. Japan Blood Cancer Drugs Market Overview  

    9.2. Japan Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    9.3. Japan Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    10. Australia Blood Cancer Drugs Market  

    10.1. Australia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    10.2. Australia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    11. Indonesia Blood Cancer Drugs Market  

    11.1. Indonesia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    11.2. Indonesia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    12. South Korea Blood Cancer Drugs Market  

    12.1. South Korea Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    12.2. South Korea Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    13. Western Europe Blood Cancer Drugs Market  

    13.1. Western Europe Blood Cancer Drugs Market Overview

    13.2. Western Europe Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    13.3. Western Europe Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    14. UK Blood Cancer Drugs Market  

    14.1. UK Blood Cancer Drugs Market Overview

    14.2. UK Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    14.3. UK Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    15. Germany Blood Cancer Drugs Market  

    15.1. Germany Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    15.2. Germany Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    16. France Blood Cancer Drugs Market  

    16.4. France Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    16.5. France Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    17. Eastern Europe Blood Cancer Drugs Market  

    17.1. Eastern Europe Blood Cancer Drugs Market Overview

    17.2. Eastern Europe Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    17.3. Eastern Europe Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    18. Russia Blood Cancer Drugs Market  

    18.1. Russia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    18.2. Russia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    19. North America Blood Cancer Drugs Market  

    19.1. North America Blood Cancer Drugs Market Overview

    19.2. North America Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    19.3. North America Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    20. USA Blood Cancer Drugs Market  

    20.1. USA Blood Cancer Drugs Market Overview

    20.2. USA Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    20.3. USA Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    21. South America Blood Cancer Drugs Market  

    21.1. South America Blood Cancer Drugs Market Overview

    21.2. South America Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    21.3. South America Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    22. Brazil Blood Cancer Drugs Market  

    22.1. Brazil Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    22.2. Brazil Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    23. Middle East Blood Cancer Drugs Market  

    23.1. Middle East Blood Cancer Drugs Market Overview

    23.2. Middle East Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    23.3. Middle East Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    24. Africa Blood Cancer Drugs Market  

    24.1. Africa Blood Cancer Drugs Market Overview

    24.2. Africa Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    24.3. Africa Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion

    25. Blood Cancer Drugs Market Competitive Landscape And Company Profiles

    25.1. Blood Cancer Drugs Market Competitive Landscape

    25.2. Blood Cancer Drugs Market Company Profiles

    25.2.1. Amgen Inc.

    25.2.1.1. Overview

    25.2.1.2. Products and Services

    25.2.1.3. Strategy

    25.2.1.4. Financial Performance

    25.2.2. AstraZeneca PLC

    25.2.2.1. Overview

    25.2.2.2. Products and Services

    25.2.2.3. Strategy

    25.2.2.4. Financial Performance

    25.2.3. Bayer AG

    25.2.3.1. Overview

    25.2.3.2. Products and Services

    25.2.3.3. Strategy

    25.2.3.4. Financial Performance

    25.2.4. Celgene Corporation

    25.2.4.1. Overview

    25.2.4.2. Products and Services

    25.2.4.3. Strategy

    25.2.4.4. Financial Performance

    25.2.5. Eli Lilly

    25.2.5.1. Overview

    25.2.5.2. Products and Services

    25.2.5.3. Strategy

    25.2.5.4. Financial Performance

    26. Key Mergers And Acquisitions In The Blood Cancer Drugs Market

    27. Blood Cancer Drugs Market Trends And Strategies

    28. Product Pipeline Analysis

    29. Blood Cancer Drugs Market Future Outlook and Potential Analysis

    30. Appendix

    30.1. Abbreviations

    30.2. Currencies

    30.3. Research Inquiries

    30.4. The Business Research Company

    30.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2014-2018, $ Billion
  • Table 2: Global Forecast Market Growth, 2014-2022F, 2025F, 2030F, $ Billion
  • Table 3: Global Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 4: Global Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 5: Global Blood Cancer Drugs Market, Split By Region, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 6: Global Blood Cancer Drugs Market, Split By Country, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 7: Asia-Pacific, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 8: Asia-Pacific, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 9: China, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 10: China, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 11: India, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 12: India, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 13: Japan, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 14: Japan, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 15: Australia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 16: Australia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 17: Indonesia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 18: Indonesia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 19: South Korea, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 20: South Korea, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 21: Western Europe, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 22: Western Europe, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 23: UK, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 24: UK, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 25: Germany, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 26: Germany, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 27: France, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 28: France, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 29: Eastern Europe, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 30: Eastern Europe, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 31: Russia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 32: Russia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 33: North America, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 34: North America, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 35: USA, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 36: USA, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 37: South America, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 38: South America, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 39: Brazil, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 40: Brazil, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 41: Middle East, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 42: Middle East, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 43: Africa, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 44: Africa, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Table 45: Amgen Inc. Financial Performance
  • Table 46: AstraZeneca PLC Financial Performance
  • Table 47: Bayer AG Financial Performance
  • Table 48: Celgene Corporation Financial Performance
  • Table 49: Eli Lilly Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2014-2018, $ Billion
  • Figure 2: Global Forecast Market Growth, 2014-2022F, 2025F, 2030F, $ Billion
  • Figure 3: Global Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 4: Global Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 5: Global Blood Cancer Drugs Market, Split By Region, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 6: Global Blood Cancer Drugs Market, Split By Country, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 7: Asia-Pacific, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 8: Asia-Pacific, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 9: China, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 10: China, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 11: India, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 12: India, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 13: Japan, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 14: Japan, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 15: Australia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 16: Australia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 17: Indonesia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 18: Indonesia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 19: South Korea, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 20: South Korea, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 21: Western Europe, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 22: Western Europe, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 23: UK, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 24: UK, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 25: Germany, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 26: Germany, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 27: France, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 28: France, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 29: Eastern Europe, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 30: Eastern Europe, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 31: Russia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 32: Russia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 33: North America, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 34: North America, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 35: USA, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 36: USA, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 37: South America, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 38: South America, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 39: Brazil, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 40: Brazil, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 41: Middle East, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 42: Middle East, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 43: Africa, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 44: Africa, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
  • Figure 45: Amgen Inc. Financial Performance
  • Figure 46: AstraZeneca PLC Financial Performance
  • Figure 47: Bayer AG Financial Performance
  • Figure 48: Celgene Corporation Financial Performance
  • Figure 49: Eli Lilly Financial Performance
Research And Development Initiatives Taken In The Anti-Infective Drugs Market
Research Initiatives And Funding And Demand For New Medicines For Drug-Resistant Infections In The Anti-Infective Drugs Industry
Global Biologics Market, Opportunities And Strategies Market | Characteristics, Forecast Size, Trends
Biologics Market By Types (Monoclonal Antibodies, Therapeutic Proteins And Vaccines), By Trends, By Regions and By Key Players - Global Forecast To 2021
View Report
Pharmaceutical Drugs Market By Segments (Musculoskeletal Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Central Nervous System Drugs, Genito-Urinary Drugs, Respiratory Diseases Drugs, Gastrointestinal Drugs, Hematology Drugs, Dermatology Drugs, Ophthalmology Drugs) - Global Forecast To 2022
View Report
Cardiovascular Drugs Global Market Report 2019
View Report
Dermatology Drugs Global Market Report 2019
View Report
Gastrointestinal Drugs Global Market Report 2019
View Report
Hematology Drugs Global Market Report 2019
View Report
Metabolic Disorders Drugs Global Market Report 2019
View Report
Musculoskeletal Disorders Drugs Global Market Report 2019
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)